A Phase 2 interventional study of Brepocitinib in Dermatomyositis and Dermatomyositis, Adult Type, sponsored by Priovant Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-20.
Sponsored by Priovant Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.
Among the 94 studies in Dermatomyositis with a site in United States, this one is the 64th largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2024, is one of 31 in phase 2, and was the 74th registered.
184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.
Browse Dermatomyositis studies →30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 18–62
Fate Therapeutics · Sites in United States
Ages 18–70
University of Miami · Sites in United States
Ages 18+
Cartesian Therapeutics · Sites in United States
Ages 12+
Restem, LLC. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 42 · Phase 3 17 · Phase 4 2
First in 1990; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Median enrollment 25 across the 73 interventional studies, 540 across the 18 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 94 have an industry lead sponsor. The 10 most frequent:
Priovant Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Priovant Therapeutics, Inc. has 2 studies filed under Dermatomyositis — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatomyositis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284954argenxA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | 2026-11 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT06298019Stanford UniversityStudy of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis | 2027-04 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07486869University of MiamiEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Dermatomyositis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Brepocitinib
Oral Brepocitinib PO QD
The primary endpoint is the change in CDASI-A score from baseline through Week 12
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Feb 2025, 6 months.
Of 19 phase 2 interventional studies under Dermatomyositis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841
Priovant Therapeutics, Inc.